EQL Pharma out-licenses Memprex (methenamine hippurate) to Laboratoires Majorelle for the French market
EQL has entered into an exclusive license agreement for the French market for EQL’s product Memprex with Laboratoires Majorelle, a French leading company in women’s health.Memprex is a methenamine hippurate-based medicine indicated for the prophylaxis of recurrent urinary tract infection (UTI). Methenamine hippurate was launched by EQL in Sweden in 2019, in the UK (via partner) in 2020 and in Norway in 2021. EQL's ambition is to offer Methenamine, using our own brand Memprex, to all other interesting markets in Europe via out-licensing. Methenamine hippurate is the only substance that is